Ren Li, Yu Yang, Wang Xia, Ge Jie, Wen Liujing
Department of Clinical Laboratory, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention & Therapy, Tianjin; Key Laboratory of Breast Cancer Prevention & Therapy, Tianjin Medical University, Ministry of Education, Tianjin 300060, China. Email:
Zhonghua Yi Xue Za Zhi. 2014 Sep 16;94(34):2656-60.
To explore the expression level and clinical significance of interleukin-11 (IL-11) in the tissue and serum samples of in breast cancer bone metastasis patients.
Peripheral blood samples were collected from 180 breast cancer patients at Tianjin Medical University Cancer Hospital from May 2007 to January 2009 and confirmed by histological pathology. According to the occurrence of bone metastases, they were divided into 2 groups of bone metastasis (MBC-B) and without bone metastasis (PBC) (n = 90 each). Another 20 healthy controls were selected from the same hospital during the same period after excluding a history of endocrine and metabolic diseases and other chronic diseases. Peripheral blood samples were collected to detect the expression level of IL-11 by enzyme-linked immunosorbent assay. At the same time, tumor tissue samples were collected from 40 breast cancer patients with bone metastasis and 40 breast cancer patients without bone metastasis. And their complete archive data were available. The expression levels of IL-11 in tumor tissue samples were detected by tissue chip and immunohistochemistry. The IL-11 mRNA expression levels of different breast tissue samples were analyzed by fluorescent quantitative reverse transcription-polymerase chain reaction (RT-PCR). Independent prognostic indicators of postoperative patient survival were screened and layered by the median level of serum concentration. Log-rank test was employed for survival analysis.
The serum concentrations of IL-11 in MBC-B, PBC and healthy control groups were (242.9 ± 56.3), (85.9 ± 35.7) and (66.4 ± 20.3) µg/L. And it had statistically significant difference (F = 43.532, P < 0.05); MBC-B group was significantly higher than PBC group (t = 40.44, P < 0.001). High expression rates of IL-11 were 57.5% and 14.3% in MBC-B and PBC groups. MBC-B group was significantly higher than PBC group (χ² = 36.626, P < 0.01). The survival time of breast cancer patients with bone metastases and high levels of IL-11 was 25.2 months and it was shorter than those with bone metastases and low levels of IL-11 (44.6 months). The difference was statistically significant (χ² = 9.550, P < 0.01).
The expression level of IL-11 is associated with the occurrence of bone metastasis in breast cancer. And breast cancer with a high expression level of IL-11 may be more susceptible to bone metastases.
探讨白细胞介素-11（IL-11）在乳腺癌骨转移患者组织及血清样本中的表达水平及临床意义。
收集2007年5月至2009年1月在天津医科大学肿瘤医院就诊的180例乳腺癌患者的外周血样本，并经组织病理学确诊。根据是否发生骨转移，将其分为骨转移组（MBC-B）和无骨转移组（PBC），每组各90例。同期从该院选取20例健康对照者，排除内分泌及代谢疾病史等其他慢性病病史。采集外周血样本，采用酶联免疫吸附测定法检测IL-11的表达水平。同时，收集40例有骨转移的乳腺癌患者及40例无骨转移的乳腺癌患者的肿瘤组织样本，且其完整存档资料可用。采用组织芯片及免疫组化法检测肿瘤组织样本中IL-11的表达水平。采用荧光定量逆转录-聚合酶链反应（RT-PCR）分析不同乳腺组织样本中IL-11 mRNA的表达水平。以血清浓度的中位数水平进行分层，筛选术后患者生存的独立预后指标，并进行生存分析。采用对数秩检验进行生存分析。
MBC-B组、PBC组及健康对照组血清IL-11浓度分别为（242.9±56.3）、（85.9±35.7）及（66.4±20.3）μg/L，差异有统计学意义（F = 43.532，P < 0.05）；MBC-B组显著高于PBC组（t = 40.44，P < 0.001）。MBC-B组和PBC组IL-11高表达率分别为57.5%和14.3%，MBC-B组显著高于PBC组（χ² = 36.626，P < 0.01）。IL-11水平高的乳腺癌骨转移患者生存时间为25.2个月，短于IL-11水平低的乳腺癌骨转移患者（44.6个月），差异有统计学意义（χ² = 9.550，P < 0.01）。
IL-11表达水平与乳腺癌骨转移的发生有关，IL-11高表达的乳腺癌可能更易发生骨转移。
